Madrigal Pharmaceuticals MDGL Cash Flow Statement (2010-2026)

NASDAQ MDGL
$541.19 -1.42 (-0.26%)
As of: Sep 4, 2026 · 2:21 PM EDT
Reported Financials

Madrigal Pharmaceuticals Quarterly Cash Flow Statement

Periods 65 quarters
Latest Jun 2026

Madrigal Pharmaceuticals reported cash from operations of $23.33M and free cash flow of $19.08M for the quarter ended Jun 2026, up 149.6% year over year. This cash flow statement covers 65 quarters of results from Jun 2010 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-63.10M-64.55M-57.52M-70.73M-81.20M-85.91M-76.90M-85.80M-98.74M-112.19M-147.54M-151.97M-106.96M-59.42M-73.24M-42.27M-111.12M-58.45M-92.30M-57.14M
Share-based CompensationStock Comp.
6.24M6.36M7.48M7.94M8.12M8.08M11.25M10.97M12.66M-33.28M19.90M24.40M1.20M0.20M20.93M25.16M26.25M25.79M34.02M35.37M
Asset Writedowns and ImpairmentWritedown
10.40M
Cash from OperationsCash from Ops.
-45.56M-48.05M-49.91M-57.36M-59.07M-58.52M-84.07M-75.31M-84.92M-79.93M-149.16M-134.94M-66.98M-104.49M-88.89M-47.05M79.85M-133.46M-167.44M23.33M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
0.18M0.31M0.31M0.43M0.55M0.67M0.75M0.66M0.47M0.48M0.48M0.44M0.37M0.33M0.47M0.45M0.46M
Depreciation & Amortization (CF)Dep. & Amort.
0.10M0.11M0.11M0.11M0.12M0.13M0.12M0.13M0.14M0.14M0.17M0.27M0.30M0.36M0.38M0.38M0.36M0.39M0.39M0.38M
Change in Working Capital
Change in ReceivablesChange Receivables
6.90M23.56M23.36M7.61M17.80M34.05M21.19M52.88M4.96M
Change in InventoryChange Inventory
0.85M6.22M1.64M25.35M21.17M8.26M5.82M1.73M22.19M11.46M
Change in Account PayablesChange Payables
9.35M10.96M1.40M-11.49M7.27M5.27M-11.70M5.41M-0.99M11.50M-11.51M-7.53M36.97M-2.37M-1.54M-4.08M5.96M4.94M3.58M-21.14M
Change in Accured ExpensesChange Accured Exp.
3.26M-3.45M-1.61M18.39M7.76M11.86M-5.89M-3.81M0.85M7.37M2.29M23.34M15.39M-6.31M-0.53M33.31M187.54M-88.42M4.29M71.25M
Investing Activities
Capital ExpendituresCapex
0.05M0.11M0.05M0.10M0.03M0.03M0.04M0.07M0.34M1.04M0.36M0.13M0.78M0.20M0.86M-0.39M3.85M4.25M
Sales of Property, Plant and EquipmentPP&E (Sale)
Change in Acquisitions & DivestmentsChange Acquisitions
155.44M70.50M93.55M98.27M79.37M79.20M11.99M88.21M119.39M113.80M182.61M163.82M214.42M302.43M294.69M273.39M275.07M240.15M353.87M187.30M
Cash from Investing ActivitiesCash from Investing
40.09M15.64M55.93M19.24M65.14M66.39M-186.86M-3.73M50.20M-362.12M98.05M-122.10M-202.39M-47.95M163.88M47.86M-207.00M27.58M192.19M34.20M
Financing Activities
Other financing activitiesOther financing
0.01M8.64M1.74M2.33M3.11M
Cash from Financing ActivitiesCash from Financing
21.10M19.50M49.11M264.34M52.69M42.93M19.58M479.92M573.71M134.12M7.46M19.77M8.64M1.74M236.65M8.96M2.33M3.11M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
17.90M6.25M1.93M244.21M311.56M85.95M-0.02M8.64M1.74M17.73M9.94M
Additional items
Exchange Rate EffectFX Effect
1.32M0.06M
Change in Cash
15.63M-12.90M6.01M10.99M6.07M272.21M-218.24M-36.11M-15.14M37.86M522.60M-122.92M-261.91M-132.66M83.63M2.55M109.50M-96.91M28.41M60.69M
Free Cash FlowFCF
-45.61M-48.16M-49.97M-57.46M-59.10M-58.54M-84.10M-75.38M-85.26M-80.97M-149.51M-135.08M-67.76M-104.68M-88.89M-47.05M78.99M-133.07M-171.28M19.08M
Net Cash FlowNCF
15.63M-12.90M6.01M10.99M6.07M272.21M-218.24M-36.11M-15.14M37.86M522.60M-122.92M-261.91M-132.66M83.63M2.55M109.50M-96.92M27.09M60.64M